1. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4:236-248.

2. Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDs. 2006;20:489-501.

3. Mandell GL, Bennett JE, Dolin R (comps.). Principles and Practice of Infectious Diseases. 6a. ed., Filadelfia: Elsevier Churchill Livingstone; 2005:1477-2133.

4. Meanwell N, Kadow JF. Inhibitors of the entry of HIV into host cells. Curr Opin Drugs Disc Devel. 2003;6:451-461.

5. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996;16:53-65.

6. Johnson VA, Brun-Vezinet F, Clotet B, y cols. Update of the drug resistance mutations in HIV-1: Otoño 2006. Top HIV Med. 2006;14:125-130.

7. US Department of Health and Human Services. Guidelines for the use of antiretrovirals in HIV-1-infected adults and adolescents 2006. Disponible en: Consultado el 28 de febrero de 2007.

8. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331:1368-1374.

9. von Moltke LL, Greenblatt DJ, Granda BW, y cols. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001;41:85-91.

10. Fontas E, van Leth F, Sabin CA, y cols. Lipid profiles in HIVinfected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.

11. Mallon PWG. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev. 2007;9:3-15.

12. Liang J-S, Distler O, Cooper DA, y cols. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001;7:1327-1331.

13. Smith JH, Martin GJ, Decker CF. Hyperlipidemia associated with the use of protease inhibitors. Clin Infect Dis. 2000;31:207-208.

14. Westby M, lineaewis M, Whitcomb J, y cols. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909-4920.

15. Greenberg ML, Cammack N. Resistance to enfuviritide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004;54;333-340.

16. Fuzeon Prescribing Information. Roche Pharmaceuticals, Nutley, NJ. Enero de 2007.

17. Chiu TK, Davies DR. Structure and function of HIV-1 integrase: an update. Front Med Chem. 2006;3:1-20.

18. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol. 1995;69:376-386.

19. Hazuda DJ. Inhibitors of human immunodeficiency virus type 1 integration. Curr Opin HIV AIDS. 2006;1:212-217.

20. Lin C-W, Engelman A. The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. J Virol. 2003;77:5030--5036.

21. Chen JCH, Krucinski J, Miercke LJW, y cols. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA. 2000;97:8233-8238.

22. Gallay P, Hope T, Chin D, Trono D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci USA. 1997;94:9825-9830.

23. Emiliani S. Mousnier A, Busschots K, y cols. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem. 2005;280:25517-25523.

24. Bushman FD, Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc Natl Acad Sci USA. 1991;88:1339-1343.

25. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell. 1991;67:1211-1221.

26. Marcello A. Latency: the hidden HIV-1 challenge [Review]. Retrovirology. 2006;3:7. Disponible en: Consultado el 27 de abril de 2007.

27. Chun T-W, Stuyver L, Mizell SB, y cols. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA.1997;94:13193-13197.

28. Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors, an emerging clinical reality. Drugs R D. 2007;8:155-168.

29. Cahn P, Sued O. Raltegravir: a new antiretroviral class for salvage therapy. Lancet. 2007;369:1235-1236.

30. Markowitz M, Morales-Ramirez JO, Nguyen BY; for Protocol 004 Study Team. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1–infected individuals. J Acquir Immune Defic Syndr. 2006;43:509–515.

31. Grinsztejn B, Nguyen BY, Katlama C, y cols. for Protocol 005 Study Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261–1269.

32. ISENTRESS (raltegravir) Worldwide Product Circular. Filename: ISENTRESS WPC 07-2007. Julio de 2007. Páginas 1–31.

Derechos reservados ©2019  Merck Sharp & Dohme I.A. Corp. Una subsidiaria de Merck & Co., Inc., Kenilworth, NJ, USA. Todos los derechos reservados.
Este sitio es solamente para los residentes de Centroamérica y República Dominicana